BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 7722313)

  • 1. Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
    Frey AB
    J Immunol; 1995 May; 154(9):4613-22. PubMed ID: 7722313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
    Frey AB; Cestari S
    Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
    Xiang J; Moyana T
    Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice.
    Belardelli F; Ferrantini M; Santini SM; Baccarini S; Proietti E; Colombo MP; Sprent J; Tough DF
    Cancer Res; 1998 Dec; 58(24):5795-802. PubMed ID: 9865738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
    Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
    Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
    Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
    Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
    Ilkovitch D; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
    Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E
    J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
    Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
    Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
    J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class I- and class II-reactive TCRs coexpressed on CD4+ T cells both trigger CD4/CD8-shared and CD4-unique functions.
    Asnagli H; Schmitt-Verhulst AM; Guimezanes A
    J Immunol; 1997 May; 158(10):4533-42. PubMed ID: 9144464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced cell-mediated cytotoxicity by interferon-gamma and interleukin-2 against syngeneic murine mammary adenocarcinoma.
    Nakajima I; Chu TM
    Mol Biother; 1992 Mar; 4(1):47-52. PubMed ID: 1627274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor activity of class II MHC antigen-restricted cloned autoreactive T cells. II. Novel immunotherapy of B16 melanomas by local and systemic adoptive transfer.
    Shiohara T; Moellmann G; Jacobson K; Kuklinska E; Ruddle NH; Lerner AB
    J Immunol; 1987 Mar; 138(6):1979-86. PubMed ID: 3493292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T; Harada M; Tamada K; Abe K; Nomoto K
    Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrosarcoma cells expressing allogeneic MHC Class II antigens induce protective antitumor immunity.
    Leach DR; Callahan GN
    J Immunol; 1995 Jan; 154(2):738-43. PubMed ID: 7814880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
    Grangeon C; Cormary C; Douin-Echinard V; Favre G; Couderc B; Tilkin-Mariamé AF
    Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.